Drug Discovery

Pfizer and Abu Dhabi partner to boost sickle cell disease research

The Department of Health (DoH) Abu Dhabi in the UAE has entered into a memorandum of understanding (MoU) with Pfizer Gulf to bolster research in areas including sickle cell disease (SCD).

Telix seeks BLA for TLX250-CDx aimed at kidney cancer imaging

Telix Pharmaceuticals has completed Biologics License Application (BLA) submission to the US Food and Drug Administration (FDA) for TLX250-CDx (Zircaix), a radiodiagnostic agent for identifying clear cell renal cell carcinoma (ccRCC) in kidney cancer patients.

Weave Bio secures $10m in seed funding round

Weave Bio has secured $10m in a seed funding round spearheaded by Innovation Endeavors and Magnetic Ventures.

ExpressionEdits secures $13m to develop protein-based therapies

UK-based biotechnology company ExpressionEdits has secured $13m in a seed funding round to advance the development of protein based therapies leveraging artificial intelligence (AI)-driven intronization technology.

Lucy Therapeutics secures $12.5m for neurological treatment development

Lucy Therapeutics (LucyTx) has secured $12.5m in additional financing round to advance the development of new treatments for Alzheimer's and Parkinson's diseases.

RevolKa signs deal with Daiichi Sankyo for functional proteins

Venture-backed biotechnology company RevolKa has entered into a master service agreement with Daiichi Sankyo for functional proteins.

Radar Therapeutics secures $13.4m to develop programmable medicines

Radar Therapeutics has successfully completed an oversubscribed seed funding round, raising $13.4m for developing smart programmable medicines.

Teva and Alvotech launch SIMLANDI in US for arthritis

Teva and Alvotech have announced the US launch of SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to the reference product Humira to treat arthritis.

ERS Genomics and IRBM sign deal for CRISPR technology

ERS Genomics and IRBM have entered into a non-exclusive license agreement, granting the latter access to ERS Genomics' extensive clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 patent portfolio.